NovoCure Limited (NVCR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 220.71M USD | Liabilities, Current |
| Cash and equivalents | 93.70M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 99.13M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 42.22M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $220.71M | $93.70M | (m) | $99.13M | $42.22M | (m) |
| 2026-03-31 | (m) | $217.58M | $87.53M | (m) | $93.27M | $43.46M | (m) |
| 2025-12-31 | (m) | $223.23M | $93.55M | (m) | $89.44M | $41.11M | (m) |
| 2025-09-30 | (m) | $776.01M | $342.12M | (m) | $85.23M | $39.10M | (m) |
| 2025-06-30 | (m) | $749.63M | $149.62M | (m) | $89.92M | $40.21M | (m) |
| 2025-03-31 | (m) | $743.30M | $127.28M | (m) | $84.51M | $39.47M | (m) |
| 2024-12-31 | (m) | $756.38M | $163.77M | (m) | $74.23M | $35.09M | (m) |
| 2024-09-30 | (m) | $735.00M | $185.42M | (m) | $67.06M | $39.10M | (m) |
| 2024-06-30 | (m) | $169.18M | $164.80M | (m) | $64.70M | $40.44M | (m) |
| 2024-03-31 | (m) | $160.23M | $453.76M | (m) | $65.09M | $42.39M | (m) |
| 2023-12-31 | (m) | $179.12M | $240.82M | (m) | $61.22M | $38.15M | (m) |
| 2023-09-30 | (m) | $157.16M | $154.86M | (m) | $65.13M | $36.81M | (m) |
| 2023-06-30 | (m) | $150.09M | $156.98M | (m) | $70.99M | $33.02M | (m) |
| 2023-03-31 | (m) | $148.78M | $185.96M | (m) | $74.83M | $31.72M | (m) |
| 2022-12-31 | (m) | $158.78M | $115.33M | (m) | $86.26M | $29.38M | (m) |
| 2022-09-30 | (m) | $141.08M | $243.81M | (m) | $87.55M | $26.79M | (m) |
| 2022-06-30 | (m) | $135.40M | $367.01M | (m) | $97.56M | $29.53M | (m) |
| 2022-03-31 | (m) | $127.80M | $190.74M | (m) | $100.97M | $29.08M | (m) |
| 2021-12-31 | (m) | $142.60M | $208.80M | (m) | $93.57M | $24.43M | (m) |
| 2021-09-30 | (m) | $124.55M | $689.84M | (m) | $94.13M | $22.64M | (m) |
| 2021-06-30 | (m) | $116.21M | $349.12M | (m) | $90.44M | $26.69M | (m) |
| 2021-03-31 | (m) | $110.49M | $314.55M | (m) | $92.51M | $27.97M | (m) |
| 2020-12-31 | (m) | $113.61M | $234.67M | (m) | $96.70M | $27.42M | (m) |
| 2020-09-30 | (m) | $95.33M | $234.46M | (m) | $84.56M | $26.48M | (m) |
| 2020-06-30 | (m) | $85.12M | $196.78M | (m) | $76.03M | $26.14M | (m) |
| 2020-03-31 | (m) | $84.20M | $181.92M | (m) | $65.14M | $22.50M | (m) |
| 2019-12-31 | (m) | $86.31M | $177.32M | (m) | $58.86M | $23.70M | (m) |
| 2019-09-30 | (m) | $80.41M | $208.03M | (m) | $49.90M | $24.39M | (m) |
| 2019-06-30 | (m) | $73.57M | $180.07M | (m) | $42.53M | $25.45M | (m) |
| 2019-03-31 | (m) | $70.95M | $152.07M | (m) | $39.22M | $24.14M | (m) |
| 2018-12-31 | (m) | $64.56M | $140.62M | (m) | $36.52M | $22.55M | (m) |
| 2018-09-30 | (m) | $48.09M | $122.96M | (m) | $35.39M | $21.64M | (m) |
| 2018-06-30 | (m) | $45.25M | $114.46M | (m) | $37.64M | $19.91M | (m) |
| 2018-03-31 | (m) | $44.76M | $111.60M | (m) | $34.04M | $20.39M | (m) |
| 2017-12-31 | (m) | $50.20M | $78.59M | (m) | $29.57M | $22.02M | (m) |
| 2017-09-30 | (m) | $40.98M | $82.10M | (m) | $23.00M | $24.64M | (m) |
| 2017-06-30 | (m) | $35.17M | $80.19M | (m) | $13.89M | $25.15M | (m) |
| 2017-03-31 | (m) | $31.91M | $84.59M | (m) | $11.82M | $25.95M | (m) |
| 2016-12-31 | (m) | $36.88M | $99.78M | (m) | $6.34M | $25.55M | (m) |
| 2016-09-30 | (m) | $29.71M | $115.82M | (m) | (m) | $23.97M | (m) |
| 2016-06-30 | (m) | $34.62M | $80.87M | (m) | (m) | $21.21M | (m) |
| 2016-03-31 | (m) | $29.43M | $115.93M | (m) | (m) | $16.45M | (m) |
| 2015-12-31 | (m) | $28.63M | $119.42M | (m) | (m) | $13.59M | (m) |
| 2015-09-30 | (m) | $25.91M | $110.32M | (m) | (m) | $11.15M | (m) |
| 2015-06-30 | (m) | (m) | $106.51M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $74.22M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $17.67M | $57.61M | (m) | (m) | $3.45M | (m) |
| 2014-09-30 | (m) | (m) | $79.98M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $175.89M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $34.89M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |